Madrigal Pharmaceuticals, Inc. (MDGL)
Stock Price:
$130.99 USD
-0.39 (-0.30%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.02B |
| Revenue (ttm) |
100,000 |
| Net Income (ttm) |
-134.33M |
| Shares Out |
15.44M |
| EPS (ttm) |
-8.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$130.99 |
| Previous Close |
$131.38 |
| Change ($) |
-0.39 |
| Change (%) |
-0.30% |
| Day's Open |
132.42 |
| Day's Range |
129.41 - 132.98 |
| Day's Volume |
65,818 |
| 52-Week Range |
56.82 - 136.13 |
More Stats
| Market Cap |
2.02B |
| Enterprise Value |
1.64B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.44M |
| Float |
10.08M |
| EPS (basic) |
-8.71 |
| EPS (diluted) |
-8.71 |
| FCF / Share |
-5.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.46M |
| Short Ratio |
12.92 |
| Short % of Float |
24.36% |
| Beta |
1.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
20,222.37 |
| PB Ratio |
5.90 |
| Revenue |
100,000 |
| Operating Income |
-142.48M |
| Net Income |
-134.33M |
| Free Cash Flow |
-78.82M |
| Net Cash |
383.86M |
| Net Cash / Share |
24.86 |
| Gross Margin |
n/a |
| Operating Margin |
-142,481.00% |
| Profit Margin |
n/a |
| FCF Margin |
-78,823.00% |
| ROA |
-20.75% |
| ROE |
-33.59% |
| ROIC |
-40.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (17)
| Buy |
13 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$172.67*
(31.82% upside)
Low
114
Current: $130.99
High
230
Target: 172.67
*Average 12-month price target from 15 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | 0.15 | 7.58 | 14.80 |
| Revenue Growth | - | - | - | - | - | - | - | -98.06% | -48.77% | - |
| Gross Profit | - | - | - | - | - | - | - | 0.15 | 7.58 | 14.80 |
| Operating Income | -94.97 | -40.68 | -32.06 | -25.22 | -3.23 | -83.95 | -87.56 | -60.94 | -45.43 | -36.90 |
| Net Income | -83.95 | -32.81 | -31.15 | -26.39 | -6.84 | -86.16 | -90.19 | -62.79 | -47.38 | -37.47 |
| Shares Outstanding | 15.39 | 14.80 | 12.24 | 5.20 | 0.17 | 2.81 | 2.03 | 1.70 | 1.35 | 1.15 |
| Earnings Per Share | -5.45 | -2.22 | -2.54 | -5.07 | -40.03 | -30.45 | -44.45 | -37.10 | -35.00 | -32.55 |
| Operating Cash Flow | -41.62 | -25.51 | -22.32 | -17.61 | -3.14 | -78.93 | -77.41 | -54.14 | -47.30 | -38.20 |
| Capital Expenditures | -0.17 | -0.02 | -0.13 | 0.70 | - | -0.14 | -0.77 | -0.51 | -0.69 | -0.14 |
| Free Cash Flow | -41.80 | -25.53 | -22.44 | -16.91 | -3.14 | -79.07 | -78.18 | -54.64 | -47.99 | -38.34 |
| Cash & Equivalents | 439 | 484 | 192 | 40.50 | 0.31 | 97.69 | 91.48 | 101 | 39.73 | 50.97 |
| Total Debt | 0.68 | - | - | - | 48.60 | 13.91 | 23.40 | 12.40 | 16.65 | 15.23 |
| Net Cash / Debt | 438 | 484 | 192 | 40.50 | -48.29 | 83.78 | 68.08 | 88.20 | 23.08 | 35.75 |
| Assets | 442 | 485 | 192 | 41.21 | 0.36 | 101 | 95.20 | 103 | 42.32 | 54.07 |
| Liabilities | 25.49 | 8.44 | 10.05 | 4.80 | 49.28 | 35.54 | 46.11 | 27.95 | 27.55 | 30.59 |
| Book Value | 417 | 477 | 182 | 36.41 | -48.91 | 65.14 | 49.09 | 75.07 | 14.77 | 23.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Madrigal Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
29 |
| CEO |
Paul A. Friedman |
Stock Information
| Ticker Symbol |
MDGL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MDGL |
Description
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.